by The global pulmonary arterial hypertension market size was estimated to be around US$ 7.3 billion in 2022. It is projected to reach US$ 12.18 billion by 2032, indicating a CAGR of 5.30% from 2023 to 2032.
Key Takeaways
- North America led the market with the largest market share of 41% in 2022.
- Asia-Pacific is projected to grow at a notable CAGR of 13.3% during the forecast period.
- By Drug Class, the prostacyclin and prostacyclin analogs segment has held the major revenue share of 45% in 2022.
- By Drug Class, The SGC simulators segment is anticipated to grow at a CAGR of 5% during the projected period.
- By Type, the branded segment contributed more than 42% of revenue share in 2022.
- By Type, the generics segment is projected to grow at the fastest CAGR over the projected period.
- By Route of Administration, the oral segment generated more than 51% of revenue share in 2022.
- By Route of Administration, the intravenous/ subcutaneous segment is expected to expand at the fastest CAGR over the projected period.
The market research report on the Pulmonary arterial hypertension market provides a comprehensive analysis of various key aspects. It includes the definition, classification, and application of Pulmonary arterial hypertension products. The report examines the development trends, competitive landscape, and industrial chain structure within the industry. Furthermore, it presents an overview of the industry, analyzes national policies and planning, and offers insights into the latest market dynamics and opportunities at a global level.
Get a Sample: https://www.precedenceresearch.com/sample/3432
Pulmonary Arterial Hypertension Market Scope
| Report Coverage | Details |
| Growth Rate from 2023 to 2032 | CAGR of 5.3% |
| Market Size in 2023 | USD 7.65 Billion |
| Market Size by 2032 | USD 12.18 Billion |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Drug Class, By Type, and By Route of Administration |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: Fiber Based Packaging Market Size to Garner USD 527.71 Billion by 2032
The report presents the volume and value-based market size for the base year 2022 and forecasts the market’s growth between 2023 and 2032. It estimates market numbers based on product form and application, providing size and forecast for each application segment in both global and regional markets.
Focusing on the global Pulmonary arterial hypertension market, the report highlights its status, future forecasts, growth opportunities, key market players, and key market regions such as the United States, Europe, and China. The study aims to present the development of the Pulmonary arterial hypertension market by considering factors like Year-on-Year (Y-o-Y) growth, in addition to Compound Annual Growth Rate (CAGR). This approach enables a better understanding of market certainty and the identification of lucrative opportunities.
Regarding production, the report investigates the capacity, production, value, ex-factory price, growth rate, and market share of major manufacturers, regions, and product types. On the consumption side, the report focuses on the regional consumption of Pulmonary arterial hypertension products across different countries and applications.
Buyers of the report gain access to verified market figures, including global market size in terms of revenue and volume. The report provides reliable estimations and calculations for global revenue and volume by product type from 2023 to 2032. It also includes accurate figures for production capacity and production by region during the same period.
The research includes product parameters, production processes, cost structures, and data classified by region, technology, and application. Furthermore, it conducts SWOT analysis and investment feasibility studies for new projects.
This in-depth research report offers valuable insights into the Pulmonary arterial hypertension market. It employs an objective and fair approach to analyze industry trends, supporting customer competition analysis, development planning, and investment decision-making. The project received support and assistance from technicians and marketing personnel across various links in the industry chain.
The competitive landscape section of the report provides detailed information on Pulmonary arterial hypertension market competitors. It includes company overviews, financials, revenue generation, market potential, research and development investments, new market initiatives, global presence, production sites, production capacities, strengths and weaknesses, product launches, product range, and application dominance. However, the data points provided only focus on the companies’ activities related to the Pulmonary arterial hypertension market.
Prominent players in the market are expected to face tough competition from new entrants. Key players are targeting acquisitions of startup companies to maintain their dominance. The report
Reasons to Purchase this Report:
- Comprehensive market segmentation analysis incorporating qualitative and quantitative research, considering the impact of economic and policy factors.
- In-depth regional and country-level analysis, examining the demand and supply dynamics that influence market growth.
- Market size in USD million and volume in million units provided for each segment and sub-segment.
- Detailed competitive landscape, including market share of major players, recent projects, and strategies implemented over the past five years.
- Comprehensive company profiles encompassing product offerings, key financial information, recent developments, SWOT analysis, and employed strategies by major market players.
Key Players
- Actelion Pharmaceuticals (now part of Janssen Pharmaceuticals)
- Gilead Sciences
- United Therapeutics Corporation
- GlaxoSmithKline
- Bayer
- Pfizer
- Arena Pharmaceuticals
- Reata Pharmaceuticals
- Lung Biotechnology
- Acceleron Pharma
- Liquidia Technologies
- SteadyMed Therapeutics (acquired by United Therapeutics)
- Complexa Inc.
- Bellerophon Therapeutics
- Innoven Life Sciences.
Market Segmentations
By Drug Class
- Endothelin Receptor Antagonists (ERAs)
- PDE-5 Inhibitors
- Prostacyclin and Prostacyclin Analogs
- SGC Stimulators
By Type
- Branded
- Generics
By Route of Administration
- Oral
- Intravenous/ subcutaneous
- Inhalational
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
TABLE OF CONTENT
By Drug Class
- Endothelin Receptor Antagonists (ERAs)
- PDE-5 Inhibitors
- Prostacyclin and Prostacyclin Analogs
- SGC Stimulators
By Type
- Branded
- Generics
By Route of Administration
- Oral
- Intravenous/ subcutaneous
- Inhalational
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
